NSE · SAROJA
Saroja Pharma Industries India Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹54 Cr with net profit ₹1 Cr — a 1.92% net margin, versus 2.15% the period before.
Shareholding
As of 2026-03-31
- Promoter73.02%
- Public26.98%
413 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.14× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Chemicals · ranked #1 of 159 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Pidilite Industries Ltd. | ₹1,65,890 Cr | 286.45 | 15.31 | 22.61% | 16.77% |
| Solar Industries India Ltd. | ₹1,63,606 Cr | 298.74 | 26.05 | 26.72% | 17.05% |
| SRF Ltd. | ₹78,369 Cr | 134.68 | 5.58 | 13.07% | 13.01% |
| Linde India Limited | ₹57,332 Cr | 104.57 | 13.44 | 12.87% | 21.69% |
| Gujarat Fluorochemicals Ltd. | ₹50,334 Cr | 461.91 | 6.45 | 7.3% | 11.49% |
| Godrej Industries Ltd. | ₹43,559 Cr | 98.05 | 3.9 | 11.1% | 5.58% |
| Navin Fluorine International Ltd. | ₹38,965 Cr | 183.04 | 9.8 | 16.69% | 20.02% |
| Himadri Speciality Chem Limited | ₹38,845 Cr | 193.44 | 8.25 | 15.96% | 16.12% |
| Deepak Nitrite Ltd. | ₹22,840 Cr | 103.95 | 3.91 | 9.43% | 6.98% |
| Deepak Fertilisers & Petrochemicals Corp Ltd. | ₹20,530 Cr | 147.31 | 3 | 10.77% | 6.41% |
| Saroja Pharma Industries India Ltd.(this company) | — | 7.46 | 0.7 | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashSaroja Pharma Industries India Ltd. has a market capitalization of Rs 16 Cr. The company reported revenue of Rs 53.91 Cr and an EPS of 4.02. Its debt-to-equity ratio stands at 0.5.
Positives
- +The company's debt-to-equity ratio is 0.5.
- +Promoter holding is 73.0182% as of Mar 2026.
- +There are no reported promoter share pledges.
Negatives
- −The company's Return on Equity (ROE) is not available.
- −The company's profit margin is not available.
- −No dividend yield has been reported for the company.
- −Revenue growth data is not available.
Financial Performance
The company's revenue was Rs 53.91 Cr. Annual revenue has shown fluctuations, decreasing from Rs 55.9567 Cr in Mar 2022 to Rs 40.8625 Cr in Mar 2024, before increasing to Rs 53.912 Cr in Mar 2025. Net profit also varied, reaching Rs 1.1401 Cr in Mar 2022, then declining to Rs 0.8783 Cr in Mar 2024, and rising to Rs 1.0342 Cr in Mar 2025.
Profitability & Returns
Saroja Pharma Industries India Ltd. reported an EPS of 4.02. The Return on Capital Employed (ROCE) is 12.57%. Annual EPS has seen variations, decreasing from 3.96 in Mar 2022 to 2.49 in Mar 2024, and then increasing to 2.57 in Mar 2025.
Balance Sheet
The debt-to-equity ratio of the company is 0.5. The book value per share is 43.01.
Ownership & Pledges
As of Mar 2026, promoters held 73.0182% of the company's shares. Public shareholding was 26.9818%. There are no reported pledged shares by the promoters. Over the periods from Mar 2024 to Mar 2026, promoter holding remained constant at 73.0182%.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Saroja Pharma Industries India Ltd.share price & fundamentals